National Cancer Institute, National Institutes of Health, Bethesda, MD
Rosa Nadal , Amir Mortazavi , Mark N. Stein , Sumanta K. Pal , Daniel K Lee , Howard L. Parnes , Yang-Min Ning , Lisa M. Cordes , Mohammadhadi H. Bagheri , Ryan Thompson , Christian Mayfield , Seth M. Steinberg , Paul Monk III, Primo Lara Jr., Rene Costello , Piyush K. Agarwal , Donald Bottaro , William L. Dahut , Andrea B. Apolo
Background: Preliminaryclinical activity of CaboNivo and CaboNivoIpi has been previously reported for mUC pts and other genitourinary tumors. Here, we report longer follow-up data of CaboNivo and CaboNivoIpi in pts with mUC nCPI and safety and preliminary clinical activity of CaboNivo in mUC rCPI Methods: This phase 1 dose + expansion cohorts study enrolled mUC nCPI (escalating doses of CaboNivo n = 15 and CaboNivoIpi n = 8) and mUC rCPI (Cabo40-Nivo3mg/kg n = 7) pts until progression/unacceptable toxicity. Objectives: Safety, ORR, DOR, PFS and OS. Tumors were assessed for response q8wks (RECIST 1.1). Adverse events (AEs) were graded (G) by NCI-CTCAE v4.0. Results: 30 mUC pts enrolled. Median follow-up: whole cohort: 11.9 months; mUC rCPI: 5.6 months. All G clinical AEs in ≥20% (n = 29): fatigue (83%), diarrhea (72%) and anorexia (62%); laboratory AEs: ALT elevation (55%), AST elevation (48%) and hyponatremia (48%). Common ≥G3 clinical AEs: fatigue (17%), HTN (14%), thromboembolic events (14%); laboratory AEs: lipase elevation (31%), hypophosphatemia (17%), hyponatremia (10%). Immune-related AEs 14% (n = 4): mUC nCPI: CaboNivo: G3 meningitis; G3 pneumonitis; CaboNivoIpi: G3 colitis; mUC rCPI: G2 adrenal insufficiency. For mUC nCPI CaboNivo ORR: 50% (6/12), mDOR: 24.1months(mo) [95% CI: 7.8 mo-not reached (NR)]; mPFS 24.1mo [95% CI:1.6mo-NR] & mOS: NR. For mUC nCPI CaboNivoIpi: ORR: 33% (2/6), mDOR: NR; mPFS 10.1mo [95% CI:1.6 mo-NR] & mOS: NR. For mUC rCPI CaboNivo, ORR: 28% (2/7), SD 57% (4/7) and DOR: 100% at 5mo. Conclusions: Both CaboNivo and CaboNivoIpi are safe and active in mUC nCPI pts, CaboNivo is also active in mUC pts previously treated with immunotherapy, suggesting the addition of Cabo to Nivo may aid in overcoming CPI resistance. Clinical trial information: NCT02496208
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Shailender Bhatia
2023 ASCO Annual Meeting
First Author: Dirk Schadendorf
2022 ASCO Annual Meeting
First Author: Charlee Nardin
2018 Genitourinary Cancers Symposium
First Author: Rosa Maria Nadal